Aptamer Group赢得了360 000英镑的合同,为放射性制药公司研制癌症定向粘合器,并扩大到一个7.5B市场。 Aptamer Group won a £360,000 contract to develop cancer-targeting binders for radiopharmaceuticals, expanding into a $7.5B market.

Aptamer Group plc赢得了与一家全球顶尖制药公司签订的360 000英镑服务费合同,以开发针对癌症的定向放射药剂的Optimer粘合器,利用该平台的强肿瘤渗透率和低免疫力。 Aptamer Group plc has won a £360,000 fee-for-service contract with a top global pharmaceutical company to develop Optimer® binders for targeted radiopharmaceuticals aimed at cancer, leveraging the platform’s strong tumor penetration and low immunogenicity. 该项目以PET成像工具为起点,旨在治疗性应用,标志着Aptamer公司向75亿美元的定向放射制药市场扩张。 The project begins with PET imaging tools and aims toward therapeutic applications, marking Aptamer’s expansion into the $7.5 billion targeted radiopharmaceutical market. 公司目前在年度合同价值可见性方面拥有103万英, 销售额为340万英, 包括与顶级制药公司达成的协议以及与Invizius进行炎症疾病治疗的协议. The company now has £1.03 million in contract value visibility for the year, with a £3.4 million sales pipeline, including agreements with top pharma firms and a therapeutic deal with Invizius for inflammatory diseases. 首席执行官Arron Tolley博士称该合同为价值透视点,突出表明行业对其技术的兴趣日益增加。 CEO Dr. Arron Tolley called the contract a value inflection point, highlighting growing industry interest in its technology.